These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11602476)

  • 1. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients.
    Marasini B; Gagetta M; Rossi V; Ferrari P
    Ann Rheum Dis; 2001 Nov; 60(11):1046-9. PubMed ID: 11602476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.
    Kallenberg CG; Wouda AA; Hoet MH; van Venrooij WJ
    Ann Rheum Dis; 1988 Aug; 47(8):634-41. PubMed ID: 3261966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon.
    Wollersheim H; Thien T; Hoet MH; Van Venrooy WJ
    Eur J Clin Invest; 1989 Dec; 19(6):535-41. PubMed ID: 2515974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
    Kallenberg CG; Pastoor GW; Wouda AA; The TH
    Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antinuclear antibodies in primary biliary cirrhosis].
    Mzali S; Johanet C; Chrétien P; Abuaf N
    Gastroenterol Clin Biol; 1989; 13(8-9):690-5. PubMed ID: 2680726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical correlation of anticentromere antibodies.
    Zuber M; Gotzen R; Filler I
    Clin Rheumatol; 1994 Sep; 13(3):427-32. PubMed ID: 7835004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological features of patients with primary biliary cirrhosis (PBC) overlapping systemic sclerosis: a comparison with patients with PBC alone.
    Akimoto S; Ishikawa O; Takagi H; Miyachi Y
    J Gastroenterol Hepatol; 1998 Sep; 13(9):897-901. PubMed ID: 9794187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early detection of connective tissue disease in patients with Raynaud's phenomenon.
    Kallenberg CG
    Rheum Dis Clin North Am; 1990 Feb; 16(1):11-30. PubMed ID: 2406802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary biliary cirrhosis-related autoantibodies in a large cohort of italian patients with systemic sclerosis.
    Cavazzana I; Ceribelli A; Taraborelli M; Fredi M; Norman G; Tincani A; Satoh M; Franceschini F
    J Rheumatol; 2011 Oct; 38(10):2180-5. PubMed ID: 21921093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity of antinuclear antibodies in primary biliary cirrhosis.
    Chou MJ; Lee SL; Chen TY; Tsay GJ
    Ann Rheum Dis; 1995 Feb; 54(2):148-51. PubMed ID: 7702406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis.
    Mandai S; Kanda E; Arai Y; Hirasawa S; Hirai T; Aki S; Inaba N; Aoyagi M; Tanaka H; Ikeda T; Tamura T; Sasaki S
    Clin Exp Nephrol; 2013 Jun; 17(3):405-10. PubMed ID: 23268283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.
    Vázquez-Abad D; Grodzicky T; Senécal JL
    Clin Immunol; 1999 Feb; 90(2):182-9. PubMed ID: 10080829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis.
    Shoji I; Takagi T; Kasukawa R
    Intern Med; 1992 Dec; 31(12):1348-55. PubMed ID: 1284406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and immunological characterization of patients with systemic sclerosis overlapping primary biliary cirrhosis: a comparison with patients with systemic sclerosis alone.
    Akimoto S; Ishikawa O; Muro Y; Takagi H; Tamura T; Miyachi Y
    J Dermatol; 1999 Jan; 26(1):18-22. PubMed ID: 10063207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies.
    Earnshaw W; Bordwell B; Marino C; Rothfield N
    J Clin Invest; 1986 Feb; 77(2):426-30. PubMed ID: 3511098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis.
    Granito A; Muratori P; Muratori L; Pappas G; Cassani F; Worthington J; Ferri S; Quarneti C; Cipriano V; de Molo C; Lenzi M; Chapman RW; Bianchi FB
    Aliment Pharmacol Ther; 2007 Sep; 26(6):831-8. PubMed ID: 17767467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical significance of anti-ENA antibodies and anticentromere antibody (ACA) in patients with sclerodermatous skin changes and Raynaud's phenomenon].
    Uchida K; Kondo H; Kashiwazaki S
    Ryumachi; 1984 Aug; 24(4):241-9. PubMed ID: 6334895
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis.
    Liberal R; Grant CR; Sakkas L; Bizzaro N; Bogdanos DP
    Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):572-85. PubMed ID: 23876351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
    Chen ZY; Fedrick JA; Pandey JP; Silver R; Maricq HR; Fudenberg HH; Dobson RL; Ainsworth SK
    Arch Dermatol; 1985 Mar; 121(3):339-44. PubMed ID: 3883903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.